The first device capable of activating a light-activated drug by remote control has been designed
A wireless device capable of remotely activating a photopharmaceutical with proven therapeutic effect has been designed
A wireless device capable of remotely activating a photopharmaceutical with proven therapeutic effect has been designed
The combination of tebentafusp and IL-2 could benefit metastatic uveal melanoma patients.
A new combined strategy to overcome immune resistance in metastatic uveal melanoma Read More »
The Catalan Society of Psychiatry and Mental Health has recognized the contribution of both professionals, national and international leaders in clinical psychology
Zongertinib could become a new tool in the treatment of HER-2 mutated lung cancer, specially for an specific group of patients
New oral drug shows high efficacy in HER2-mutated lung cancer Read More »
A type of autoantibodies is demonstrated to be an independent risk factor for the severity of COVID-19
New study on the causes of severe COVID-19 in vaccinated patients Read More »
Kleptomania is described for the first time not only as an impulsive disorder, but also as a compulsive disorder.
Kleptomania: Bellvitge leads a new approach in the study and treatment of the disease Read More »
The new tools are highly efficient, operate at colder temperatures, and appear to be more specific than the canonical system.
Dr. Roser Velasco, IDIBELL principal investigator at Neuro-Oncology group and neurologist at the Neuro-Oncology Unit of ICO Hospitalet and Bellvitge University Hospital, has co-directed the writing of an international guide of recommendations on the management of neurological complications associated with CAR-T cell therapy. Dr. Velasco has participated as an expert in neuro-oncology within the Committee
Megaloencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare childhood disease that mainly affects the white matter of the brain. Among other symptoms, it is characterized by macrocephaly, inability to coordinate motor movements, and epilepsy. More than 75% of diagnosed cases are due to mutations in the MLC1 gene, which encodes a protein located in
Gene therapy reverses the symptoms of a rare neurological disease in animal models Read More »
The significant increase in serious infections caused by S.dysgalactiae is confirmed, reaffirming the need to strengthen detection and surveillance systems